User discusses two medications for stopping hair loss: Fin (finasteride) and Dut (dutasteride). Mixed experiences and side effects are shared, with some users seeing positive results.
Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.
A user shared their experience with hair loss treatments, including RU58841, ketoconazole shampoo, caffeine shampoo, and topical finasteride. They found RU58841 effective for diffuse thinning but experienced severe hair loss after stopping it; topical finasteride worked well for a receding hairline but caused side effects. They also use a charcoal shampoo and practice scalp massages.
Hair regrowth treatments for cis-males include Minoxidil, Finasteride, and RU58841. Estrogen and testosterone blockers can help restore hair loss but may not suit everyone.
Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.
A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.
The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It also mentions ongoing human trials for hair multiplication/cloning at Yokohama National University, with skepticism about the timeline.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Vitamin D may counteract DHT and help with hair growth, as seen in mice and human hair cultures. Some users discuss using Vitamin D, magnesium, and other supplements for hair health, while others humorously note the success in mice.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
The conversation is about hair loss treatments, specifically discussing the effectiveness of Red Ginseng Extract in promoting hair growth. Other treatments mentioned include Minoxidil, finasteride, and RU58841.
The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.
The conversation humorously suggests that a character named Finn from "Adventure Time" is named after finasteride, a hair loss treatment, and jokes about a correlation between the character and hair loss. Specific treatments mentioned are finasteride (Fin).
Yokohama University and Dr. Fukuda plan human hair multiplication trials in 2023. Users express hope for future hair cloning treatments over current hair transplants.
A new hair loss treatment using dermal exosomes can restore up to 90% of lost hair in mice. Users discuss potential human trials and compare it to Minoxidil and Finasteride.
The conversation discusses the safety and effectiveness of continuing or adding RU58841 after stopping finasteride for hair loss treatment. One user expresses skepticism about using RU58841 due to the lack of full human trials.
Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.
The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.
Researchers finding that microRNA can potentially regrow 90% of lost hair, and the challenges involved in moving this research forward to human trials. Various treatments for hair loss, such as finasteride and minoxidil, have been discussed.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
Peppermint oil may accelerate hair growth, but its effectiveness for regrowing hair or restoring a receding hairline lacks evidence from human studies or personal experiments. Some online examples exist, but they may be biased by product sales.
A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.
Dutasteride may be better for the brain than Finasteride, potentially increasing dopamine levels and causing fewer side effects. For those switching from Finasteride to Dutasteride to prevent hair loss, it's recommended to continue Finasteride for 3-4 months while starting Dutasteride to avoid shedding due to Dutasteride's long half-life.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.
This conversation is a humorous discussion about the effects of Minoxidil and Finasteride on hair growth, with some users speculating that it may have turned the poster into a "scientific horror story".